Search Weight Loss Topics:

Page 63«..1020..62636465..7080..»

Home » Testosterone » Page 63

Guys, if youre having problem with your sexual performance or suffering from erectile dysfunction (ED), get your heart health checked. A study published in the Journal of the Endocrine Society suggested that erectile dysfunction could also be a sign of a mans risk for cardiovascular disease and early death. This risk exists regardless of your testosterone levels. Also Read - Men with erectile dysfunction at high risk of death: Know the factors leading to this problem

Erectile dysfunction, also known as impotence, is characterized by the inability to develop or maintain an erection of the penis during sexual activity. This condition occurs more often in older men, and it is more often linked to low levels of testosterone. In previous studies, low testosterone levels have been linked to a higher risk of death in middle-aged and older men. But those results have been inconsistent, said Dr. Leen Antonio of KU Leuven-University Hospitals in Belgium, the lead researcher on the new study. Also Read - Indiscriminate use of marijuana ups your risk of heart ailments

Dr. Antonios team examined the relationship between hormone levels and sexual function in men. Surprisingly, they found that having erectile dysfunction is a bigger issue than low testosterone levels. Also Read - Not satisfied with your sex life? Some sexual health issues you shouldnt ignore in the New Year

As both vascular disease and low testosterone levels can influence erectile function, sexual symptoms can be an early sign for increased cardiovascular risk and mortality, said Antonio.

Dr. Antonios team analyzed data from nearly 2,000 men ages 40 to 79 in five medical centres. They examined the relationship between their hormone measurements and sexual function. During the average follow-up period of 12.4 years, 25 per cent of the men died. Of the men who died, those with normal testosterone levels and erectile dysfunction had a 51% higher risk of death than those without these symptoms.

They also found that men with low total testosterone levels and sexual symptoms had a higher risk of death compared with men with normal testosterone levels and no sexual symptoms.

Higher risk of early death was found in men with sexual symptoms such as erectile dysfunction and poor morning erections. But the researchers didnt find association of low libido with a higher risk of early death.

In addition to low testosterone levels, erectile dysfunction may result from clogged arteries, or cardiovascular disease, which can impede the blood flow necessary to create an erection. Thats why erectile dysfunction, regardless of testosterone levels, can indicate a risk for heart disease and early death.

According to Dr. Antonio, the blood vessels that provide blood for an erection are smaller than the coronary arteries. This means that when theres a build-up of plaque in the arteries (atherosclerosis) the blood flow in the penile vessels may be affected earlier than in the coronary arteries.

Some other possible causes of erectile dysfunction include

Erectile dysfunction can be both prevented and treated by practicing a healthy lifestyle, Dr. Antonio said. Treating heart disease risk factors such as smoking, high blood pressure, high cholesterol and obesity may also help prevent the sexual disfunction, the researcher suggested.

Antonio noted that sexual symptoms could be an early warning sign of poor or worsening health status as well as an increased risk for cardiovascular disease and mortality.

So, it is important to discuss sexual symptoms with your doctors to identify and treat other cardiovascular risk factors or apparent cardiovascular disease, the study author added.

Published : April 30, 2020 10:54 pm

Go here to see the original:
Erectile dysfunction is more than a sexual problem - it could be an early sign of cardiovascular disease - TheHealthSite

For most women, perimenopause the transition to menopause begins in their 40s. The entire menopause process typically lasts around four years and begins with the ovaries making less estrogen.

A woman is considered to be post-menopausal when she hasnt experienced a menstrual period for 12 months. This usually occurs between the ages of 46 to 52 years.

Read more: How to make work menopause-friendly: don't think of it as a problem to be managed

Symptoms of menopause can include irregular periods, hot flushes, fatigue, tender breasts, night sweats, vaginal dryness, difficulty sleeping, changes in mood and lower libido.

During menopause, hormonal changes can affect the way fat is distributed in the body, but ageing is more likely to be the cause of any weight gain associated with menopause.

Gaining weight isnt inevitable, though. Theres plenty you can do to combat weight gain as you age.

Certain areas such as your stomach are more prone to weight gain during menopause. This is because the change in hormones, which lead to a higher testosterone-to-estrogen ratio, alters where the body deposits fat. Fat comes off the hips and is deposited around the middle.

But the hormonal changes involved in menopause arent the reason you gain weight.

The weight gain that comes with menopause is a by-product of ageing.

As we age, our body stops working as efficiently as it did before. Muscle mass starts to decrease a process known as sarcopenia and fat begins to increase.

And because muscle mass is one of the determining factors of how fast your metabolism will run, when your muscle mass decreases, your body starts to burn fewer calories at rest. This might make it more challenging to maintain your weight.

Read more: Trick or treat? Alternative therapies for menopause

As we age, we tend to continue with our same food habits but dont increase our activity. In fact, aches and pains can make some people actively decrease theirs.

Not compensating for the ageing process and the change in body composition can lead to weight gain.

And this applies to men too they are just as likely to gain weight due to this process known as sarcopenia.

Due to a change in body fat distribution and increase in waist circumference, menopause can also increase your risk of other health conditions.

Read more: Hot flashes? Night sweats? Progesterone can help reduce symptoms of menopause

Following menopause, your ovaries make very little of the hormones estrogen and progesterone. Estrogen helps to keep your blood vessels dilated relaxed and open which helps keep your cholesterol levels down.

Without estrogen, or with lower quantities, your bad cholesterol (known as low-density lipoprotein or LDL-cholesterol) starts to build up in your arteries. This can increase your risk of heart disease and stroke.

Having less estrogen also results in a loss of bone mass, putting you at risk of the disease osteoporosis, which makes your bones more prone to fractures.

Weight gain associated with ageing is not inevitable. There are a number of things you can do to maintain your weight as you age.

1. Exercise

Incorporate regular daily exercise, with a mixture of intensities and variety of activities. Try to include body-strengthening exercises two days per week.

2. Weigh yourself but not too much

Weigh yourself once a week at the same time and day to monitor the trend over time. Any more than this will only create a fixation with weight. Day-to-day fluctuations in weight are to be expected.

3. Create positive habits

Create positive habits by replacing negative behaviours. For example, instead of mindlessly scrolling through social media of an evening or turning on the TV and comfort-eating, replace it with a positive behaviour, such as learning a new hobby, reading a book or going for a walk.

Read more: How to beat weight gain at menopause

4. Eat more slowly

Eat food away from technological distractions and slow down your food consumption.

Try using a teaspoon or chopsticks and chew your food thoroughly as slowing down your food consumption reduces the quantity consumed.

5. Switch off from technology:

Turn off technology after dusk to improve your sleep. Blue light emission from phones, tablets and other devices tell your brain its day, instead of night, which will keep you awake.

Lack of sleep (less than six hours per night) can compromise your decision-making abilities which might lead you to make unhealthy choices that contribute to weight gain.

6. Curb sugar cravings naturally

If youre craving sugar youre better off reaching for foods naturally high in sugar and fat first. Some great options are fruits, nuts, avocado and 100% nut butters. These foods release the same feel-good chemicals in the brain as processed and fast food and leave us feeling full.

Allow yourself your favourite treats, but keep them to once per week.

Read the original here:
Why do women gain weight during menopause? - The Conversation AU

The ' Testosterone Replacement Therapy market' research report now available with Market Study Report, LLC, is a compilation of pivotal insights pertaining to market size, competitive spectrum, geographical outlook, contender share, and consumption trends of this industry. The report also highlights the key drivers and challenges influencing the revenue graph of this vertical along with strategies adopted by distinguished players to enhance their footprints in the Testosterone Replacement Therapy market.

Request a sample Report of Testosterone Replacement Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2430747?utm_source=algosonline.com&utm_medium=sp

The latest report on the Testosterone Replacement Therapy market contains a detailed analysis of this marketplace and entails information about various industry segmentations. According to the report, the market is presumed to amass substantial revenue by the end of the forecast duration while expanding at decent growth rate.

Details regarding the industry size, remuneration potential, and volume share are compiled in the report. It further lists out the drivers and challenges that will impact the growth of Testosterone Replacement Therapy market during the estimated timeframe.

The Testosterone Replacement Therapy market with respect to the geographical terrain:

Ask for Discount on Testosterone Replacement Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2430747?utm_source=algosonline.com&utm_medium=sp

Additional highlights from the Testosterone Replacement Therapy market report are enlisted below:

Table of Contents:

Executive Summary: It includes key trends of the Testosterone Replacement Therapy market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Testosterone Replacement Therapy market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Testosterone Replacement Therapy market.

Market Segments: This part of the report discusses about product type and application segments of the Testosterone Replacement Therapy market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-testosterone-replacement-therapy-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Testosterone Replacement Therapy Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Testosterone Replacement Therapy Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Related Reports:

1. Global Type 2 Diabetes Medication Market 2020 by Company, Regions, Type and Application, Forecast to 2025The Type 2 Diabetes Medication Market Report offer the complete scenario of the industry and valuation of upcoming Trends for future market. It also gives the analytic of enduring growth factor, trends and statistic of Type 2 Diabetes Medication Market industry. The Type 2 Diabetes Medication Market has been outlined by overall information and analysis.Read More: https://www.marketstudyreport.com/reports/global-type-2-diabetes-medication-market-2020-by-company-regions-type-and-application-forecast-to-2025

2. Global Rizatriptan Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Rizatriptan Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of Rizatriptan by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchants profile, plus, advertise value examination and esteem chain highlights are canvassed in this report.Read More: https://www.marketstudyreport.com/reports/global-rizatriptan-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Reports: https://www.marketwatch.com/press-release/sterile-injectables-market-size---detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2025-2020-05-04

Related Reports: https://www.marketwatch.com/press-release/at-139-cagr-devops-tools-market-size-set-to-register-59498-million-usd-by-2025-2020-05-05

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read the rest here:
Latest Study explores the Testosterone Replacement Therapy Market Witness Highest Growth in near future - AlgosOnline

The United States District Courts for the District of New Jersey and the Southern District of New York recently dismissed putative securities class action complaints filed against life science companies in Smith v. Antares Pharma, Inc., et al. and Schaffer v. Nabriva Therapeutics PLC, et al.[1] The decisions make clear that the duty to disclose, imposed on life science companies by the federal securities laws, does not cover all conceivable information investors may find or consider relevant. Moreover, both courts held life science companies are not prohibited from expressing optimism about the prospects of FDA approval for products simply because of less-than-positive feedback from the regulator during the review process. The decisions, and their implications, are discussed below.

Antares Pharma Complaint

On December 21, 2016, Antares Pharma, Inc. (Antares) announced it submitted a New Drug Application (NDA) with respect to Phase 3 clinical studies, conducted in 2014 and 2015, for a testosterone replacement therapy (TRT) drug called QuickShot Testosterone which is currently marketed as Xyosted. Its stock price increased with the announcement. In October 2017, after Antares announced an October 11 FDA letter identifying deficiencies with the NDA, its common stock fell 37.80%. One week later, the FDA issued a Complete Response Letter (CRL) that rejected the NDA and identified clinically meaningful increases in blood pressure and incidents of depression and suicide. On January 11, 2018, Antares disclosed a 12.7% rate of hypertension observed in one of its Phase 3 studies.

Antares submitted a revised NDA in April 2018, which was approved by the FDA on October 1, 2018 with a black boxed warning for blood pressure increases, as well as warnings for risks of depression and suicide. Plaintiff contends Antaress stock price decreased 3% [o]n the heels of the revelation of approval with the requirement of a black box warning and risk of depression and suicide.

Nabriva Therapeutics Complaint

During the class period, Nabriva Therapeutics PLC (Nabriva) had only two products being considered by the FDA for marketing approval; it was not generating revenues from product sales, and did not expect to, unless one of the two drug candidates received approval. In October 2018, Nabriva filed a NDA with respect to Contepo, a drug intended to treat complicated urinary tract infections; this prompted FDA review, which would conclude with a final decision from the FDA by April 30, 2019. On December 14, 2018, the FDA issued a Form 483 letter[2] identifying inspectional observations it made, after visiting the manufacturing plant, that suggested the plant was not in compliance with applicable standards. Nabriva made several statements regarding the Contepo NDA during the class period, none of which mentioned the FDAs Form 483. Ultimately, the FDA did not approve the Contepo NDA. Instead, it issued a CRL withholding approval based substantially on the issues identified in the Form 483 letter. Upon this news, Nabrivas share price declined over 27%.

On August 16, 2019, Nabriva announced it would resubmit the Contepo NDA after rectifying the issues identified in the CRL. Because resubmission would retrigger a six-month review cycle, the FDA would likely not approve Contepo in 2019. Plaintiff alleged statements Nabriva made during the class period were misleading because they led investors to believe the FDA would approve the Contepo NDA in 2019, even though the Form 483 demonstrated that approval would be delayed beyond that year.

Dismissals of the Complaints

In both cases, the complaints were dismissed in their entireties, emphasizing that a life science companys duty to disclose is not unlimited and that it is not enough to plead that an optimistic forward-looking statement regarding approval prospects or timing of approval turns out to be incorrect.

Duty to Disclose

The Supreme Court has made clear that Section 10(b) of the Securities Exchange Act and Rule 10b5 do not create an affirmative duty to disclose any and all material information. Disclosure is required . . . only when necessary to make . . . statements made, in the light of the circumstances under which they were made, not misleading.[3]

In this vein, the Antares decision rejected plaintiffs argument that the failure to disclose the exact statistical risk of any adverse event was not actionable where the specific adverse event was identified as a common side-effect. The court similarly rejected plaintiffs allegation regarding the failure to provide data demonstrating the adverse event risks of its drug compared to the risks of other TRT treatments on the market, emphasizing that there was no duty to disclose such information unless Antares had disclosed some other comparative safety data that would render this omission misleading.

Puffery

The two dismissals also reiterate that puffery or vague statements of corporate optimism are not actionable under Section 10(b) and Rule 10b-5 because they are so general that a reasonable investor would not rely on them.

For example, the Antares court deemed statements that the drug was found to be safe, showed positive . . . safe data and that nothing unusual occurred regarding the FDAs review of the drug as vague and general statements of optimism. The court explained statements cannot be read in a vacuum, concluding a reasonable investor would understand Antaress statements on the drugs safety in light of the disclosure of adverse events. The Nabriva court similarly held company press release statements describing Contepos NDA submission as another major milestone, and Contepo as a first in class antibiotic, as classic examples of puffery because both are vaguely optimistic descriptions that make no particularly definite assertions of existing fact and thus provide little basis to mislead a reasonable investor.

Forward-Looking Statements

The dismissals also emphasized the protections afforded forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act (PSLRA).

The Nabriva court rejected challenges to statements made by the company in its March 12, 2019 10-K regarding the risk of delay in FDA approval. Plaintiff argued that the characterization of the delay as a risk rather than a certainty was misleading in light of the concerns raised in the FDAs December 2018 Form 483 and that as a result the statement was not a forward-looking statement but rather a misstatement of existing fact. The court rejected the contention that the risks identified had already materialized, reasoning that the expected approval date was still over four months away and that the Form 483 reflected interim feedback and not a final decision.

Opinions

In dismissing the complaints, the courts reiterated that interpretations of clinical data are opinions and emphasized the heightened pleading requirements with respect to opinion statements following the Supreme Courts decision in Omnicare.[4]

In Antares, the court rejected plaintiffs argument regarding the falsity of the companys opinion about the physiologically normal benefits of the drug, concluding that plaintiff had failed to allege that the opinion was either objectively or subjectively false. The court explained that incidents of hypertension, depression or suicide did not render false the companys opinion regarding the drugs ability to provide patients with physiologically normal and steady levels of testosterone.

The court also held a statement regarding the positive safety data resulting from the study was an interpretation of the clinical trial data and as such an opinion. It reasoned the statement was not actionable absent facts showing Antares did not honestly believe the studies produced positive safety data and lacked a reasonable basis. [5] Similarly, the court held plaintiff failed to allege Antares lacked a reasonable basis for its opinion that the drug was safe, and noted a failure to allege that Antares was aware of this comparative risk data when [it] made the statement.

Conclusion

Antares and Nabriva are helpful precedents for pharmaceutical companies defending against securities class action lawsuits based on optimistic statements made about products undergoing FDA approval. The decisions emphasize that alleged misstatements cannot be read in a vacuum, and indicate that plaintiffs cannot simply rely on less-than-stellar feedback from the FDA, coupled with statements of corporate optimism made during the drug approval process.

See more here:
District Courts In New Jersey And New York Dismiss Securities Class Actions Against Life Science Companies Emphasizing the High Pleading Bar With...

Hair loss is a natural part of ageing. Everyone may begin to notice the thinning of their hair as the years go by but some experience this process much more rapidly and sooner. Hair loss takes place on the surface of the skin, but the damage is far more skin deep. There is a herb which helps stimulate circulation and brings nutrients to the follicles which all aid in stimulating hair growth.

Medical News Today said: Studies show that rosemary oil extract can help reverse some of the most common forms of hair loss.

Male pattern baldness is a form of hair loss that occurs when a by-product of testosterone called dihydrotestosterone attacks the hair follicles.

Both men and women produce testosterone, but men typically produce more testosterone than women, so hair loss in men can occur more often at an earlier age, and more extensively.

Rosemary oil may help with this type of hair loss.

In a study with the US National Library of Medicine National Institutes of Health, promotion of hair growth in mice with rosemary leaf extract was investigated.

The study noted: Topical administration of rosemeary oil extract improved hair regrowth in mice that experienced hair regrowth interruption induced by testosterone treatment.

In addition, rosemary oil promoted hair growth in mice that had their dorsal areas shaved.

These results suggest that they inhibit the binding of dihydrotestosterone to androgen receptors.

Consequently, rosemary oil extract is a promising crude drug for hair growth.

In a study with Europe PMC, rosemary oil and how it could help with the treatment of androgenetic alopecia was analysed.

The study noted: Rosemary oil is a medicinal plant with diverse activities.

The present study aimed to investigate the clinical efficacy of rosemary oil in the treatment of androgenetic alopecia and compare its effects.

Patients with alopecia were randomly assigned to either rosemary oil or minoxidil for a period of six months.

The study concluded that the group which was treated with rosemary oil had more hair growth than the minoxidil group but the difference was not statistically significant.

The results suggest that rosemary oil may promote hair growth in the long term.

Here is the original post:
Hair loss treatment: A herb which improves cellular generation stimulating hair growth - Express

When Idahos governor signed a lawlast month banning transgender women and girls from competing in school athletic programs for girls, civil rights groups readied themselves for yet another constitutional fight.

The Fairness in Womens Sports Act, or HB 500, requires a student whose eligibility is in dispute to provide a doctors note that verifies her biological sex, based on one of three things: the students reproductive anatomy, genetic makeup, or normal endogenously produced testosterone levels. The law, which applies to the states public school and higher education systems, is the first of its kind.

Its hard to imagine a more invasive thing, said Nora Huppert, a fellow at Lambda Legal, a national legal organization that fights for LGBTQ civil rights. Two student-athletes are already suing the state.

Idahos governor also signed a law prohibiting people from changing the gender markers on their birth certificates to align with their gender identity.

Want our news sent to you every week?

SUBSCRIBE TODAY!

The goal ofthe legislation targeting trans athletes, experts say, isto codify discriminatory and invasive practices founded on nonscientific reasoning and personal prejudice.

Sport developed as a masculine pastimeto demonstrate manliness, and anything that challenges conventional gender norms or behavior threatens societal arrangements and expectations, said Lindsay Pieper, an associate professor of sports management atVirginias University of Lynchburgand the author of Sex Testing: Gender Policing in Womens Sports.

The law goes further than the guidance of the Idaho High School Activities Association, which was already restrictive. Like rules from the International Olympic Committee (IOC) and the National Collegiate Athletic Association (NCAA), it allowed trans girls and women to compete on womens teams if they had completed one year of hormonetherapy. The IOC policy goes further by requiring athletes to demonstrate specific testosterone levels for one year.

[Testosterone is] the only thing [the IOC is] regulating, said Kristine Newhall, assistant professor of kinesiology at SUNY Cortland. By zeroing in on testosterone levels, Newhall said, athletic governing bodies have created a measurement for sex only as it pertains to sports that has changed every so often when scientists believe they have a better way to measure sexdifference.

Weve gone through all these [measures] of sex: genitalia, secondary sex characteristics, chromosomes, and then its hormones, Newhall said, alluding to the relatively recent fixation on testosterone. What this demonstrates is that science tells us that theres no one way to measure sex.

One of the first public debates about the use of science and gender verification to dictate athletic participation was in 1976, when Rene Richards, a trans woman, applied to compete in the U.S. Open andrefused to subject herself to the chromosomal testrequired by the U.S. Tennis Association. Richards won a lawsuit the following year to compete without undergoing the test.

Though we still dont know what it means to embody a gender, sociocultural forces and athletic governing bodies are attempting to codify what it means to be a woman, Pieper said.

Hard science that measures chromosomes, genetics, or genitalia is an imperfect measurement of what it means to embody a gender, because scientific discoveries are often influenced by human prejudice, said JayCee Cooper, a 32-year-old amateur powerlifter and trans woman from Minneapolis, Minnesota. Science exists with a social underpinning. Theres no way to separate that, because we as humans naturally have biases.

Cooper knows this through her own experience. In late 2018, Cooper was prevented by USA Powerlifting from competing in the womens category, even though she adhered to the IOC standards of lowered testosterone levels. USA Powerlifting states on its website that trans women have advantages over cisgender women competitors, citing the scientific opinion of a doctorfrom the organizations own medical committee. In June 2019, Gender Justice, a nonprofit legal and policy advocacy organization, filed acomplaint against USA Powerlifting on behalf of Cooper.

Advantage isnt one thing, Newhall said, and theres no one bodily reason that an athletefares better than their competitors. Newhall noted that swimmers with bigger feet might best their fellow athletes on a given day, or that ice skaters with larger lungs might be better equipped for the sport. Congrats if you have greater lung capacity, then you have greater advantage.

Even then, many other determinantsincluding wealth and resourcesalso dictate ability to compete. The real disadvantage girls and women face in sports have to do with institutions that regulate them, said Sarah Axelson, senior director of advocacy at the Womens Sports Foundation, an organization dedicated to gender equality in sports.

Axelson called Idahos HB 500 a distraction from the real needs of girls athletics. According to the Womens Sports Foundation,87percent of NCAA-regulation schools were not in compliance with Title IX standards, which prohibit sex-based discrimination inschools that receive public funding. Girls, both trans and cis, need more opportunities for athletics, not fewer, Axelson said. Sports have tremendous power for the development of our youth.

Transgender students are disproportionately more likely than their cisgender peers to feel unsafe at school and be denied basic resources, like use of bathrooms or locker rooms that align with their gender.The new Idaho legislation will make the lives of trans students and anyone who doesnt conform with conventional gender norms more difficult, Huppert said. Theres clearly a moral panic around trans people, in particular in the states around trans kids.

Trans students also experience higher rates of stress and are at higher risk of suicide than their cis peers. HB 500 will exacerbate these issues. What [Idaho legislators] are saying is, Youre not normal, Newhall said.

Anti-trans legislation burdens trans student-athletes with having to assert the legitimacy of their embodied experiences. While Idaho lawmakers argue they are evening out the playing field, they are actually further disempowering trans youth and actively perpetuating anti-trans discrimination.

When trans athletes are able to compete, sports can be empowering and healing. Cooper said when shes competing, This is me to a 100 percent degree, and I get to define that for myself. Its something that nobody can take away. I get out on the platform and I do this thing, pushing myself completely to the limit [and] also pushing other peoples perspectives.

Link:
Idaho's New Anti-Trans Athlete Law: 'It's Hard to Imagine a More Invasive Thing' - Rewire.News

Testosterone Therapy Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Testosterone Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=115440

Top Key Players Profiled in This Report:

AbbVie Inc, Actavis Inc, Eli Lilly & Co, Auxilium Pharmaceuticals.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Testosterone Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Testosterone Therapy markets trajectory between forecast periods.

If You Have Any Query, Ask to Analyst:

https://www.a2zmarketresearch.com/enquiry?reportId=115440

Reasons for buying this report:

Table of Contents:

Global Testosterone Therapy Market Research Report

Chapter 1 Testosterone Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Testosterone Therapy Market Forecast

Buy Exclusive Research Report @:

https://www.a2zmarketresearch.com/buy?reportId=115440

If you have any special requirements, please let us know and we will offer you the report as you want.

Continue reading here:
Future Prospects of Testosterone Therapy Market 2020 | Trends, Growth Demand, Opportunities & Forecast To 2026 | AbbVie Inc, Actavis Inc, Eli...

Acerus Pharmaceuticals

Global Testosterone Replacement Therapy Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Testosterone Replacement Therapy Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Testosterone Replacement Therapy market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Testosterone Replacement Therapy market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=208345&utm_source=LHN&utm_medium=888

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Testosterone Replacement Therapy world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Testosterone Replacement Therapy market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Testosterone Replacement Therapy world industry from 2020 to 2026 is provided to determine the potential of the Testosterone Replacement Therapy market.

This Testosterone Replacement Therapy Market Report Answers To Your Following Questions:

Who are the main global players in this Testosterone Replacement Therapy market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=208345&utm_source=LHN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Testosterone Replacement Therapy Market Size, Testosterone Replacement Therapy Market Trends, Testosterone Replacement Therapy Market Growth, Testosterone Replacement Therapy Market Forecast, Testosterone Replacement Therapy Market Analysis

More here:
Testosterone Replacement Therapy Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 - Latest...

click to enlarge

CP Photo: Jared Wickerham

SisTers founder and president Ciora Thomas wand vice president Aiden James Nevils

The program, led by SisTers PGH vice president (and Thomas fiance) Aiden James Nevils, has been in the works for months. The original plan was to launch on International Transgender Day of Visibility (March 31), but when that event couldn't happen in person, Nevils still wanted to launch it virtually.

"I was like, 'Hey, if we can't announce this at our Transgender Day of Visibility, we have to let people know this is a resource for them as well because people are looking to talk,'" says Nevils. "People are looking to have some type of connection in a time when we aren't really able to connect physically."

Nevils says he was inspired by seeing Thomas' leadership in the city as a trans woman and wanted to create a space for trans men in leadership positions, too.

BroThers operates under the wider umbrella of SisTers, and Nevils describes it as a branch off of the tree in the organization's logo, adding that SisTers will always be "the roots."

"SisTers PGH has laid the groundwork for what it looks like to have trans leadership in the city," says Nevils. "The thought process behind this is we also need to have trans masculine and trans men leadership in the city as well. And also have a group where all people can come together and talk."

A primary focus of the programming, especially while everything is virtual, is a support group for trans men and trans masculine people, where they can be open and honest about their experiences. Nevils says there aren't many resources or support groups specifically for trans men and trans masculine people in Pittsburgh or anywhere else across the country. Even when there are, he says they often focus on the physical aspects of transitioning, like hormones and surgery, but not as much on the mental and emotional changes.

"When you start testosterone, there's a lot of different things that happen to your body, but no one talks about the things that happen mentally and how it works with your emotions and how you start to feel things differently," says Nevils, citing the importance of teaching people that taking testosterone is "not the end-all, be-all. It's not a cure."

Jared Wickerham

Aiden James Nevils of BroThers

The resources from SisTers and BroThers are especially important during the current pandemic, as they provide resources for a community that might not otherwise get help. For every marginalized group of people, the pandemic has further highlighted ways that governments and institutions fail to work for all people, including the trans community. Nevils points to the example of SisTers PGH's LGBTQIA Emergency Relief Fund (which has currently raised over $26,000) without which there might not be any relief fund geared at helping trans people in the city.

"When you think about the transgender community in its entirety, we're already marginalized and pushed outside the bounds of what is considered to be human," says Nevils. "This pandemic has shined a major light on how often trans people are forgotten about."

BroThers PGH is currently taking donations of physical supplies like masks and toiletries, as well as financial donations, which can be made through SisTers PGH.

Originally posted here:
Trans advocacy organization SisTers PGH branches out with BroThers PGH, a program geared at trans men - PGH City Paper

Tzido/iStock.com

By Amanda HeidtMay. 1, 2020 , 1:05 PM

A prostate cancer drug has been successfully repurposed to help men in treatment for pedophilic disorder. By blocking testosterone, the drug degarelix minimized intrusive thoughts and helped participants feel more calm and controlled in as little as 2 weeks, according to a study published this week in JAMA Psychiatry. Researchers recruited 52 volunteers from a hotline for men with self-described unwanted sexuality, and who were subsequently diagnosed with pedophilic disorder. Participants received injections of the drug and underwent risk assessment via self-reporting and psychological evaluation over the next 10 weeks. Despite some side effectsincluding hot flashes and inflammation at the site of the injectionthe majority of participants wanted to stay on the medication once the trial ended, The Guardian reports. Researchers say they hope their drug can provide fast-acting and long-lasting treatment to minimize the risk of sexual violence toward children, which is estimated to affect one in five girls and one in 10 boys worldwide.

See more here:
Cancer drug dampens intrusive thoughts in men with pedophilic disorder - Science Magazine

Page 63«..1020..62636465..7080..»

Home » Testosterone » Page 63